Table 3.
The allele and genotype frequency of TPH2 gene polymorphism in patients with LPE and controls
| SNP | Genotype | LPE | Control | OR value (95% CI) | P value | Allele | LPE | Control | OR value (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| rs11178998 | G/G | 4 | 1 | 0.914 (0.466–1.791) | .793 | G | 39 | 26 | 1.209 (0.706–2.070) | .489 |
| A/G | 31 | 24 | A | 201 | 162 | |||||
| A/A | 85 | 69 | ||||||||
| rs7305115 | G/G | 25 | 22 | 1.129 (0.709–1.796) | .610 | G | 113 | 81 | 1.194 (0.813–1.755) | .366 |
| A/G | 63 | 37 | A | 125 | 107 | |||||
| A/A | 31 | 35 | ||||||||
| SNV019 | G/G | 0 | 0 | 2.936 (1.066–8.084) | .037 | G | 22 | 9 | 2.682 (1.024–7.026) | .045 |
| A/G | 22 | 9 | A | 208 | 177 | |||||
| A/A | 93 | 84 | ||||||||
| rs1007023 | G/G | 1 | 0 | 1.383 (0.6347–3.011) | .415 | G | 26 | 18 | 1.167 (0.619–2.200) | .634 |
| T/G | 24 | 18 | T | 208 | 168 | |||||
| T/T | 92 | 75 | ||||||||
| rs4290270 | T/T | 28 | 25 | 0.616 (0.279–1.360) | .049 | T | 109 | 92 | 0.601 (0.373–0.969) | .037 |
| A/T | 53 | 42 | A | 133 | 94 | |||||
| A/A | 40 | 26 | ||||||||
| rs17110747 | A/A | 9 | 7 | 1.01 (0.5996–1.701) | .971 | A | 59 | 46 | 0.995 (0.639–1.551) | .983 |
| G/A | 41 | 32 | G | 183 | 142 | |||||
| G/G | 71 | 55 |
CI = confidence interval; LPE = lifelong premature ejaculation; OR = odds ratio; SNP = single-nucleotide polymorphism; SNV = single-nucleotide variant; TPH2 = Tryptophan Hydroxylase 2.